Concepedia

Author

Hongfu Cai

Union HospitalORCID

Also Known As

Cai, Hongfu, Hong-Fu Cai, Hongfu Cai

62

Publications

656

Citations

15

H-Index

14

Concepts

All Affiliations

Union HospitalFujian Medical UniversityCancer Hospital of Shantou University Medical CollegeShantou UniversityFujian Provincial Cancer Hospital
HC

About

Hongfu Cai is an author at Union Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

100

2

Health Sciences

2

2

37

3

Cancer Therapeutics

2

2

63

4

Health Policy

1

1

11

5

Pathology

1

1

50

Hongfu Cai

×

24

Publications

518

Citations

15

H-Index

YearCitations

Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China

Hongfu Cai, Longfeng Zhang, Na Li,

Clinical Therapeutics

2019

50

Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis

Hongfu Cai, Longfeng Zhang, Na Li,

Journal of Comparative Effectiveness Research

2020

37

First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis

Longfeng Zhang, Yongfu Hang, Maobai Liu,

Frontiers in Oncology

2020

36

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Hongfu Cai, Baohua Xu, Na Li,

Frontiers in Pharmacology

2021

34

Pharmacokinetics and cardiotoxicity of doxorubicin and its secondary alcohol metabolite in rats

Xiaofang Zeng, Hongfu Cai, Hongqiang Qiu,

Biomedicine & Pharmacotherapy

2019

32

Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Na Li, Huanrui Zheng, Yanlei Huang,

Frontiers in Pharmacology

2021

29

Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China

Na Li, Bin Zheng, Hongfu Cai,

Clinical Drug Investigation

2017

26

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More

Zhiwei Zheng, Jingrong Lin, Huide Zhu,

Frontiers in Public Health

2022

24

Preoperative Prognostic Nutritional Index Predict Survival in Patients With Resectable Esophageal Squamous Cell Carcinoma

Zhiwei Zheng, Huide Zhu, Hongfu Cai

Frontiers in Nutrition

2022

23

<p>Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer</p>

Maobai Liu, Longfeng Zhang, Qishu Huang,

Cancer Management and Research

2019

22

Page 1